Researchers suggest that clinical trial design could be shaped by measuring reductions in urinary protein.
A recent study that measured reductions in urinary protein in patients with a rare kidney disease left researchers looking for more ways to use this important marker of renal function.
An study published August 10 in the American Journal of Kidney Diseases examined the role of proteinuria in focal segmental glomerulosclerosis (FSGS), a condition in which scar tissue forms on the glomeruli, the areas of the kidneys that filter waste from the blood. FSGS is not curable, but treatment can slow its progression.
Jonathan P. Troost, PhD, of the University of Michigan in Ann Arbor, and co-authors studied the connection between reducing urinary protein through treatment and kidney survival. They examined 138 patients with steroid-resistant FSGS who had enrolled in a randomized trial that compared two drugs typically used as immunosuppressants to prevent organ rejection: cyclosporine, or mycophenolate mofetil plus dexamethasone.
Over 26 weeks, changes in urinary protein levels were significantly related to those in the estimated glomerular filtration rate (eGFR). Each 1-unit reduction in urinary protein was associated with a 3.90 mL/year increase in eGFR (95% CI=2.01 to 5.79), and this remained significant after adjusting for remission.
The results translated into survival benefits: the authors wrote that each 1-unit reduction in log-transformed urinary protein to creatinine ratio was associated with a 77% reduction in end-stage kidney disease or renal death.
Such results have many implications. “These novel findings expand on previous reports showing that complete and partial proteinuria remissions are associated with large clinical benefit, and also suggest that reduction in proteinuria — even if not to a complete remission — is still associated with improved survival,” they wrote.
Proteinuria is already an important tool in detecting renal damage, risk of infection, or finding patients at increased cardiovascular risk. Glomerular proteinuria is a key assessment of renal function. Renal outcomes have been a focus of recent trials involving sodium glucose co-transporter 2 (SGLT2) inhibitors, for example, but have focused on eGFR and CV or renal death as end points. The authors suggest adding proteinuria along with other predetermined end points in clinical trials would give researchers an additional tool to evaluate therapies.
"Reductions in proteinuria warrant further evaluation as a potential surrogate for preservation of kidney function that may inform the design of future clinical trials," they write.
Reference
Troost JP, Trachtman H, Spino C, et al. Proteinuria reduction and kidney survival in focal segmental glomerulosclerosis. Am J Kidney Dis. Published online August 10, 2020. doi:10.1053/j.ajkd.2020.04.014
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen